Siemens Medical Systems has become the second gamma camera vendor to win Food and DrugAdministration 510(k) clearance for a nonuniform attenuation correctionproduct. Siemens' Hoffman Estates, IL, nuclear medicine grouplast month got the FDA's imprimatur
Siemens Medical Systems has become the second gamma camera vendor to win Food and DrugAdministration 510(k) clearance for a nonuniform attenuation correctionproduct. Siemens' Hoffman Estates, IL, nuclear medicine grouplast month got the FDA's imprimatur to market the technique asan option for the open-configuration versions of its MultiSPECT2 and MultiSPECT 3 dual-head and triple-head gamma cameras. Siemenscompetitor Picker International was the first vendor to marketattenuation correction last year (SCAN 6/1/94).
The Siemens approach relies on offset fan-beam collimators,which have advantages over the centered fan-beam techniques usedin competing systems, according to Reinout Vogt, manager of newproduct development. A radioactive source is mounted to the sideof a detector rather than in the center, with the gamma rays detectedby the offset fan-beam collimator opposing the source. This increasesthe detector's effective field-of-view and avoids truncation artifacts,Vogt said.
The radioactive source used by the technique is americium,which has a half-life of 433 years and thus does not need to bereplaced for the life of the gamma camera. The vendor of the americiumsources has agreed to take them back when the camera is retired,Vogt said.
Siemens plans to begin shipping open-configuration MultiSPECT2 and MultiSPECT 3 cameras later this year. They can be linkedwith any DICOM 3.0-compatible workstation (SCAN 11/23/94).
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.